Raymond James Financial Services Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$307K	Buy	+4,197	New	+$315K	﹤0.01%	2940
2024 Q2	–	Sell	-4,981	Closed	-$345K	–	3540
2024 Q1	$345K	Sell	4,981 -1,459	-23%	-$100K	﹤0.01%	2756
2023 Q4	$461K	Sell	6,440 -89	-1%	-$5.12K	﹤0.01%	2481
2023 Q3	$340K	Sell	6,529 -2,290	-26%	-$133K	﹤0.01%	2565
2023 Q2	$558K	Buy	8,819 +2,770	+46%	+$173K	﹤0.01%	2284
2023 Q1	$328K	Buy	6,049 +1,859	+44%	+$89.9K	﹤0.01%	2598
2022 Q4	$222K	Buy	+4,190	New	+$210K	﹤0.01%	2804

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial Services Advisors's ITCI Position: Q3 2024 in Review

Raymond James Financial Services Advisors opened a new position in Intra-Cellular Therapies Inc. (ITCI) in Q3 2024: 4,197 shares worth $307K. The stake represents ﹤0.01% of the portfolio and ranks #2940 among its holdings. This is a return to the name: Raymond James Financial Services Advisors previously reported a position in ITCI as recently as Q1 2024.

Raymond James Financial Services Advisors first reported a position in ITCI in Q4 2022 and has held it in 7 quarters since. The position peaked at $558K in Q2 2023. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

Raymond James Financial Services Advisors held 4,197 shares of Intra-Cellular Therapies Inc. worth $307K as of Q3 2024.
Intra-Cellular Therapies Inc. was a new Raymond James Financial Services Advisors position in Q3 2024.
Intra-Cellular Therapies Inc. made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2940 holding.
Raymond James Financial Services Advisors first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and has held it in 7 quarters since.
Raymond James Financial Services Advisors's Intra-Cellular Therapies Inc. position peaked at $558K in Q2 2023.
355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.